Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new tuberculosis preventive treatment among adolescents and school staff who have been in close contact with active TB cases. This study compares a novel 1-month ultra-short regimen called 1H3P3 with the standard 3-month 3HR regimen, aiming to prevent latent TB infection from progressing to active tuberculosis. The trial is a phase 3, multi-center, open-label, cluster randomized controlled study conducted in school settings in China, with the goal of improving TB prevention strategies for adolescents. Participants are randomly assigned to receive either the 12-dose 1H3P3 regimen of isoniazid and rifapentine taken three times a week for one month, or the 3HR regimen of isoniazid and rifampicin taken once daily for three months. Close contacts of TB cases are screened using blood tests, chest X-rays, sputum testing, and symptom checks to rule out active TB before enrollment. The treatment period lasts either one or three months depending on the group, followed by two years of follow-up to monitor for TB development. During the study, participants will undergo regular assessments including monitoring for active tuberculosis through clinical and laboratory tests, adverse events, treatment adherence, and drug resistance if active TB occurs. The main measurement is the cumulative incidence of active TB over 24 months after treatment begins. Safety and treatment completion rates are tracked throughout. Participation involves screening, treatment administration, and periodic follow-up visits over two years to evaluate outcomes and overall TB prevention effectiveness.
Actively Recruiting
Researchers are studying the rate of Mycobacterium tuberculosis MTB infection among students who have been in close contact with active tuberculosis ATB patients at school. The study also aims to identify risk factors related to tuberculosis infection and evaluate the health economics of the screening strategy. This observational study is sponsored by Huashan Hospital and focuses on school contacts of ATB patients aged 13 years and older. Participants will undergo the QuantiFERON-TB Gold QFT test to determine if they have been infected with MTB. Those who test positive will have further assessments including sputum Xpert MTBRIF testing, physical examination, chest CT scan, and if necessary, sputum culture to differentiate latent TB infection from active tuberculosis. For participants over 15 years old with a positive QFT result, a chest X-ray scan may also be performed. During the study, participants will provide baseline information including age, sex, vaccination history, contact patterns, and medical history through checklists. Researchers will monitor the prevalence of tuberculosis infection at baseline and collect other relevant data. The study is observational, meaning no treatment is provided, and participants will be followed to understand the infection status and related factors. The total study duration extends until the end of 2025.
Actively Recruiting
Primary aldosteronism PA is a common cause of secondary hypertension, and its diagnosis and treatment pose significant challenges. This research investigates adrenal venous sampling AVS, which is considered the best method to distinguish between different types of PA. The study aims to address clinical, technical, and methodological questions about AVS and to understand how AVS-guided management influences long-term health and biochemical results to improve patient care. Participants with PA will undergo adrenal venous sampling through either the antecubital or femoral vein to identify whether aldosterone overproduction is unilateral or bilateral. This observational study evaluates the AVS procedure itself and its clinical outcomes, refining protocols and standardizing practices to optimize treatment decisions and patient prognosis. Throughout the study, researchers will monitor major cardiovascular events one year after AVS. They will also assess procedure success rates, complications, medication changes, blood pressure, heart and kidney function, and clinical outcomes over multiple years. The follow-up includes assessments at 1, 3, 6, 12, 18 months, and up to 10 years, enabling comprehensive evaluation of long-term effects and safety.
Actively Recruiting
Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.
Actively Recruiting
The trial investigates treatment options for patients with rifampicin-resistant tuberculosis RR-TB, including those resistant or susceptible to fluoroquinolones. It compares seven different 9-month oral drug combinations to the current 9-month standard of care for fluoroquinolone-susceptible RR-TB, and a 9-month bedaquiline-containing regimen to a 20-month conventional regimen for fluoroquinolone-resistant RR-TB. This Phase 3, randomized, controlled, open-label study aims to evaluate if these new shorter treatments are as effective and safe as existing therapies. Participants susceptible to fluoroquinolones receive one of several oral regimens combining drugs like bedaquiline, linezolid, fluoroquinolones moxifloxacin or levofloxacin, cycloserine, clofazimine, and pyrazinamide. Treatment lasts 9 months, with possible extension by 2 months for certain conditions. For fluoroquinolone-resistant participants, the experimental regimen includes bedaquiline, cycloserine, clofazimine, linezolid, and pyrazinamide for 9 months, compared to a 20-month standard regimen. Drug resistance is tested at baseline to adjust medications accordingly. During the study, participants undergo assessments including sputum culture tests and safety evaluations up to 21 months after randomization. Researchers monitor treatment outcomes such as cure rates, time to culture conversion, adverse effects severity, mortality, and specific drug-related side effects. Participants are followed closely with clinical and laboratory tests to evaluate the effectiveness and safety of these regimens throughout the treatment and follow-up period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of JX10, a thrombolytic drug, compared to a placebo in adults aged 18 to 90 who have experienced an Acute Ischemic Stroke AIS and present for care between 4.5 to 24 hours after stroke onset. The study aims to determine whether JX10 improves functional outcomes measured by the modified Rankin Scale and assess the risk of symptomatic intracranial hemorrhage associated with the treatment. The study has two parts. In Part 1, participants are randomly assigned to receive either JX10 at two different doses 1 mgkg or 3 mgkg or a placebo. In Part 2, participants receive either the optimal dose of JX10 selected from Part 1 or placebo. The study is double-blind and randomized to ensure unbiased results. Participants will be monitored for functional recovery over 90 days, with the primary outcome being the proportion of participants with no or minimal symptoms at 90 days post-treatment. Safety is tracked by recording incidence of symptomatic intracranial hemorrhage within 36 hours after randomization and adverse events throughout the study. Secondary measures include functional independence, ordinal Rankin scores, and incidence of major bleeding. The total duration of participation spans at least 90 days following treatment.
Actively Recruiting
Tuberculosis TB remains a leading infectious disease worldwide, with treatment challenges including poor adherence to long and complex regimens. Researchers are evaluating high-dose rifapentine regimens to treat rifampicin-sensitive pulmonary tuberculosis with the aim of shortening treatment duration and reducing side effects and economic burden. This multicenter, prospective, randomized controlled study focuses on assessing the safety, effectiveness, and pharmacokineticspharmacodynamics of these regimens compared to the standard treatment. The study includes four treatment groups three experimental groups receiving rifapentine at doses of 10mgkg, 15mgkg, or 20mgkg combined with isoniazid, pyrazinamide, and moxifloxacin during an 8-week intensive phase, followed by a continuation phase of 9 weeks with rifapentine, isoniazid, and moxifloxacin and one comparator group receiving the World Health Organizations standard 26-week regimen with rifampicin, isoniazid, pyrazinamide, and ethambutol. The continuation phase may be extended up to 18 weeks if certain treatment response criteria are not met. Participants will be monitored through treatment and follow-up lasting up to 108 weeks after randomization. Researchers will evaluate treatment success rates, culture conversion at various time points, relapse rates, and adverse events throughout the study period. Safety assessments will include laboratory tests and clinical evaluations to monitor tolerability and drug effects, ensuring thorough observation during and after treatment completion.
Actively Recruiting
Researchers are evaluating and comparing the effects of total intravenous anesthesia using remimazolam versus propofol in patients at moderate to high risk undergoing major elective noncardiac surgery under general anesthesia. This randomized controlled trial aims to determine if remimazolam can increase the number of days patients are alive and out of the hospital within 30 days after surgery. The study is conducted by Nanfang Hospital, Southern Medical University and is classified as a phase 4 trial. Participants receive either remimazolam or propofol as anesthesia. Remimazolam is given intravenously at 6-12 mgkgh for induction and 1.0-2.0 mgkgh for maintenance, adjusted to keep the Bispectral Index between 40 and 60. Propofol is administered intravenously at 1.5-2.5 mgkg for induction and 4-12 mgkgh for maintenance, also titrated to maintain the same Bispectral Index range. These dosing strategies help monitor and control anesthesia depth during surgery. During the study, participants will be closely monitored for outcomes including days alive and out of hospital at 30 days after randomization, all-cause mortality within 30 days, length of hospital stay, unplanned re-hospitalizations, postoperative complications, and quality of recovery on the first day after surgery. The trial involves double-blind randomization and includes follow-up assessments at 30 days to gather comprehensive data on recovery and safety.
Actively Recruiting
Researchers are evaluating a treatment for people with spontaneous supratentorial intracerebral hemorrhage ICH, a serious type of stroke caused by bleeding in the brain. The study is a phase III randomized controlled trial that will involve 768 participants to compare a new minimally invasive surgery combined with a clot-dissolving drug against standard medical care. This trial aims to assess the safety and effectiveness of using tenecteplase to liquefy and drain brain hematomas, potentially improving recovery outcomes. Participants will be randomly assigned to one of two groups. One group will receive minimally invasive stereotactic catheter placement followed by the local injection of tenecteplase to liquefy and drain the hematoma, with doses of 0.5 mg given up to four times over several days. The other group will receive standard medical treatment in line with current guidelines. The surgery uses imaging to target the hematoma, and after catheter placement, tenecteplase is carefully administered through the catheter with close monitoring. Throughout the study, participants will undergo regular assessments including neurological exams, brain imaging, and functional outcome evaluations up to 180 days after treatment. The main measurement is the modified Rankin Score assessing disability and recovery. Other outcomes include neurological improvement, hematoma size, mortality, and quality of life. Follow-up visits may be conducted face-to-face or remotely, and researchers will carefully monitor safety and treatment effects during this period.
Actively Recruiting
Researchers are evaluating whether injecting nicardipine directly into the cerebrospinal fluid improves outcomes for patients with cerebral vasospasm caused by aneurysmal subarachnoid hemorrhage. This multi-center, prospective, double-blinded, randomized controlled trial compares two methods of delivering nicardipine through extraventricular drainage EVD or lumbar drainage LD. The study aims to determine which approach leads to a better prognosis for affected patients. Participants in the treatment group receive intrathecal nicardipine injections via EVD or LD catheters. The process involves withdrawing 6 ml of cerebrospinal fluid, injecting 4 ml 4 mg of nicardipine hydrochloride, followed by 2 ml of saline, then clamping the catheter for 2 hours. This dosing is done twice daily. The control group undergoes a simulated procedure without receiving the drug. The drainage tubes remain open as clinically needed between doses. During the study, participants are monitored for outcomes using multiple scales, including the Modified Rankin Scale at 90 and 365 days, Glasgow Outcome Score, MMSE, NIH Stroke Scale, and rates of complications like infections or hemorrhage. Safety is assessed through adverse event tracking. Follow-up visits occur up to one year after treatment. The entire study period spans from the start of treatment to long-term outcome evaluations.